The CBR is integrated as a Research Group into the Life Sciences Institute (LSI). Strong academic and research ties exist, and state-of-the-art resources are shared, thereby promoting excellence and more rapid scientific advances.
	Canadian Blood Services is central to the development of the academic and training programs associated with the CBR. The organization provided matching funds for the construction of CBR space within the Life Sciences Centre and provides ongoing infrastructure support through a national competitive granting procedure. Several Canadian Blood Services investigators are active members of the CBR and UBC faculty, with fully integrated academic research and teaching programs.
	In 2009, CSL Behring Canada Inc. entered into a partnership with the CBR and the Faculty of Medicine of UBC to establish a CSL Behring Research Chair. This is currently held by Dr. Ed Conway, the CBR’s Director from 2009 – 2020. Research emanating from this important collaboration aligns the goals of the CBR to promote first-class education, training, and research with CSL Behring’s mission to develop safe and effective therapies that improve the lives of patients with rare and serious diseases. As part of their mission, CSL Behring also supports a range of educational programs and symposia at the CBR.
	In 2007, the CBR established an annual Earl W. Davie Lecture Series to honour the ground-breaking work of Dr. Davie in the field of hemostasis and thrombosis. This symposium, as well as several other educational programs at the CBR, is supported by generous contributions from Novo Nordisk Canada Inc.
	Since 2009, the global healthcare company Grifols (formerly Talecris Biotherapeutics), has led the way in contributing unrestricted funds to support the CBR undergraduate summer studentship program, a Collaborative Translational Training Awards Program, the CBR Weekly Seminar Series, and the Annual Norman Bethune Symposium.
	From its very inception, the CBR and Bayer Canada have been strong partners in infrastructure and training. Bayer continues to provide unrestricted funds for the CBR Seminar Series and summer studentships, and has most recently committed long-term support for the newly created UBC Bleeding Disorders Collaboratory (UBCBDC).
	Exposing our undergraduate students to hands-on opportunites in the lab and the clinic is key for the development and training of future generations of scientists and clinicians. Pfizer Canada is a major partner of the CBR in this endeavour, as they are the major  sponsor for the Annual CBR Summer Student Research Day. Pfizer also provides unrestricted educational grants for advanced clinical raining in hemostasis and thrombosis at the CBR and the affiliated university teaching hospitals.
	In 2012, Novartis Pharmaceuticals Canada is a world leader in developing medicines for a wide array of blood-related diseases, and was an important sponsor of the first Annual Norman Bethune Symposium.
	World Thrombosis Day was founded in 2014 by the International Society on Thrombosis and Haemostasis (ISTH) in response to members’ requests for a focused global awareness day on thrombosis. It is led by a global scientific steering committee who aim to focus attention on the often overlooked and misunderstood condition of thrombosis. The Centre for Blood Research has joined organizations across the world to host the Thrombosis Awareness Day on October 13. These public education events raise awareness about the causes, risk factors, signs/symptoms, and prevention of Thrombosis.

We recognize the important contributions made by numerous other private donors, not-for-profit agencies, government organizations and industrial partners that continue to support research, education, training and clinical care at the CBR.